Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sampling Plans01:23

Sampling Plans

180
Sampling is a crucial step in analytical chemistry, allowing researchers to collect representative data from a large population. Common sampling methods include random, judgmental, systematic, stratified, and cluster sampling.
Random sampling is a method where each member of the population has an equal chance of being selected for the sample. It involves selecting individuals randomly, often using random number generators or lottery-type methods. For example, when analyzing the properties of a...
180
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

36
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
36
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

119
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
119
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

172
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
172
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

120
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
120
Cluster Sampling Method01:20

Cluster Sampling Method

11.8K
Appropriate sampling methods ensure that samples are drawn without bias and accurately represent the population. Because measuring the entire population in a study is not practical, researchers use samples to represent the population of interest.
To choose a cluster sample, divide the population into clusters (groups) and then randomly select some of the clusters. All the members from these clusters are in the cluster sample. For example, if you randomly sample four departments from your...
11.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Surgical Margins: Fully Mature Tertiary Lymphoid Structures (fmTLSs) Are Predictive Biomarkers for Local Recurrence in Primary Soft-Tissue Sarcomas.

Cancers·2026
Same author

Empirical Comparison of Win Ratio and Joint Frailty Models for Recurrent Event Endpoints With Applications in Oncology and Cardiology.

Statistics in medicine·2026
Same author

Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France.

Dermatology and therapy·2026
Same author

Metastatic Ewing Sarcoma, Patterns of Care and Outcomes of Patients in a Real-Life National Setting Over a Decade.

Cancer medicine·2026
Same author

Mediation Analysis With Bayesian Nonlinear Joint Models: Evaluation of the Treatment Causal Pathways Between Tumor Growth Kinetics and Overall Survival.

Statistics in medicine·2026
Same author

The DeepJoint Algorithm: An Innovative Approach for Studying the Longitudinal Evolution of Quantitative Mammographic Density and Its Association With Screen-Detected Breast Cancer Risk.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K

Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker-Strategy Designs With Multiple

Derek Dinart1,2, Virginie Rondeau1,3, Carine Bellera1,2

  • 1Bordeaux Population Health Research Center, Epicene Team, U1219, University of Bordeaux, Inserm, Bordeaux, France.

Pharmaceutical Statistics
|July 17, 2024
PubMed
Summary
This summary is machine-generated.

Biomarker-strategy design (BSD) optimizes personalized medicine by comparing treatment strategies. A new simulation method using a partially clustered frailty model (PCFM) helps estimate sample sizes for these trials.

Keywords:
biomarker‐strategyfrailty modelheterogeneityrandomizedsample size

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Related Experiment Videos

Last Updated: Jun 21, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Personalized Medicine

Background:

  • Biomarker-guided therapy is advancing medical research.
  • Optimizing biomarker use requires innovative study designs.
  • Biomarker-strategy design (BSD) focuses on treatment strategies, not just molecules.

Purpose of the Study:

  • To propose a simulation method for sample size estimation in biomarker-strategy designs (BSD) with multiple targeted treatments.
  • To evaluate factors influencing sample size in BSD.
  • To offer an alternative to traditional sample size calculation methodologies.

Main Methods:

  • A simulation method based on a partially clustered frailty model (PCFM) was developed.
  • An extension of the Freidlin formula was used for sample size estimation.
  • The method was applied to BSD with multiple targeted treatments.

Main Results:

  • The proposed PCFM simulation method provides sample size estimates for BSD.
  • Key factors influencing sample size include treatment effect heterogeneity, proportion of biomarker-negative patients, and randomization ratio.
  • The PCFM is suitable for the data structure in BSD.

Conclusions:

  • The PCFM-based simulation method is a viable approach for sample size calculation in biomarker-strategy designs.
  • This method offers an alternative to traditional statistical methodologies for complex trial designs.
  • Accurate sample size estimation is crucial for the success of biomarker-guided therapeutic strategies.